ACELYRIN IncNASDAQ:SLRN
- LAST PRICE4.2400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.3000/ 70
- Ask / Lots4.6000/ 15
- Open / Previous Close4.2500 / 4.2400
- Day Range
- 52 Week Range
- Volume657,192
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SLRN |
|---|---|---|
| 09:32 ET | 9269 | 4.215 |
| 09:34 ET | 361 | 4.215 |
| 09:36 ET | 1425 | 4.19 |
| 09:38 ET | 9420 | 4.23 |
| 09:39 ET | 900 | 4.2259 |
| 09:41 ET | 2800 | 4.25 |
| 09:43 ET | 100 | 4.255 |
| 09:48 ET | 100 | 4.255 |
| 09:50 ET | 8168 | 4.225 |
| 09:52 ET | 100 | 4.225 |
| 09:54 ET | 200 | 4.225 |
| 09:56 ET | 6554 | 4.29 |
| 09:57 ET | 6879 | 4.27 |
| 09:59 ET | 915 | 4.25 |
| 10:01 ET | 9532 | 4.28 |
| 10:03 ET | 6979 | 4.285 |
| 10:06 ET | 12936 | 4.3 |
| 10:08 ET | 15144 | 4.28 |
| 10:10 ET | 600 | 4.28 |
| 10:12 ET | 4599 | 4.3 |
| 10:14 ET | 2123 | 4.3 |
| 10:15 ET | 633 | 4.3 |
| 10:17 ET | 625 | 4.29 |
| 10:19 ET | 1838 | 4.28 |
| 10:21 ET | 1045 | 4.29 |
| 10:24 ET | 1029 | 4.28 |
| 10:26 ET | 800 | 4.26 |
| 10:28 ET | 100 | 4.26 |
| 10:30 ET | 800 | 4.23 |
| 10:32 ET | 2585 | 4.24 |
| 10:33 ET | 502 | 4.25 |
| 10:35 ET | 1017 | 4.26 |
| 10:37 ET | 4300 | 4.28 |
| 10:39 ET | 1400 | 4.26 |
| 10:44 ET | 8425 | 4.23 |
| 10:46 ET | 9360 | 4.24 |
| 10:50 ET | 2500 | 4.25 |
| 10:51 ET | 1335 | 4.2408 |
| 10:53 ET | 400 | 4.245 |
| 10:55 ET | 100 | 4.245 |
| 10:57 ET | 2213 | 4.24 |
| 11:00 ET | 1642 | 4.255 |
| 11:02 ET | 2800 | 4.255 |
| 11:04 ET | 2100 | 4.265 |
| 11:06 ET | 547 | 4.265 |
| 11:08 ET | 400 | 4.26 |
| 11:09 ET | 3240 | 4.24 |
| 11:11 ET | 100 | 4.24 |
| 11:13 ET | 400 | 4.245 |
| 11:15 ET | 200 | 4.24 |
| 11:20 ET | 300 | 4.24 |
| 11:22 ET | 1300 | 4.235 |
| 11:24 ET | 2503 | 4.245 |
| 11:26 ET | 400 | 4.245 |
| 11:27 ET | 300 | 4.245 |
| 11:29 ET | 1100 | 4.245 |
| 11:31 ET | 4536 | 4.245 |
| 11:38 ET | 3264 | 4.245 |
| 11:40 ET | 600 | 4.24 |
| 11:42 ET | 1969 | 4.24 |
| 11:44 ET | 960 | 4.24 |
| 11:45 ET | 2825 | 4.24 |
| 11:47 ET | 300 | 4.24 |
| 11:49 ET | 600 | 4.24 |
| 11:51 ET | 500 | 4.24 |
| 11:54 ET | 11084 | 4.27 |
| 11:56 ET | 100 | 4.28 |
| 11:58 ET | 1489 | 4.28 |
| 12:00 ET | 1100 | 4.28 |
| 12:02 ET | 1400 | 4.28 |
| 12:03 ET | 700 | 4.28 |
| 12:05 ET | 700 | 4.28 |
| 12:07 ET | 300 | 4.28 |
| 12:09 ET | 1100 | 4.285 |
| 12:12 ET | 5890 | 4.29 |
| 12:16 ET | 18815 | 4.3 |
| 12:18 ET | 59989 | 4.3 |
| 12:20 ET | 787 | 4.3 |
| 12:21 ET | 5844 | 4.3 |
| 12:23 ET | 3793 | 4.3 |
| 12:25 ET | 600 | 4.3 |
| 12:27 ET | 600 | 4.3 |
| 12:30 ET | 800 | 4.3 |
| 12:32 ET | 4496 | 4.2999 |
| 12:34 ET | 2900 | 4.3 |
| 12:36 ET | 1300 | 4.3 |
| 12:38 ET | 3182 | 4.3 |
| 12:39 ET | 4201 | 4.27 |
| 12:41 ET | 1435 | 4.2765 |
| 12:43 ET | 3073 | 4.255 |
| 12:45 ET | 100 | 4.255 |
| 12:48 ET | 500 | 4.255 |
| 12:50 ET | 200 | 4.255 |
| 12:52 ET | 100 | 4.255 |
| 12:54 ET | 1791 | 4.27 |
| 12:59 ET | 200 | 4.27 |
| 01:01 ET | 100 | 4.27 |
| 01:03 ET | 1200 | 4.28 |
| 01:06 ET | 2600 | 4.295 |
| 01:08 ET | 300 | 4.295 |
| 01:10 ET | 200 | 4.295 |
| 01:14 ET | 4900 | 4.3 |
| 01:15 ET | 585 | 4.3 |
| 01:17 ET | 400 | 4.3 |
| 01:19 ET | 500 | 4.3 |
| 01:21 ET | 700 | 4.3 |
| 01:26 ET | 1300 | 4.3 |
| 01:28 ET | 995 | 4.3 |
| 01:30 ET | 300 | 4.29 |
| 01:33 ET | 100 | 4.295 |
| 01:37 ET | 100 | 4.295 |
| 01:39 ET | 300 | 4.295 |
| 01:42 ET | 800 | 4.295 |
| 01:44 ET | 400 | 4.3 |
| 01:46 ET | 4525 | 4.29 |
| 01:48 ET | 100 | 4.295 |
| 01:50 ET | 2800 | 4.3 |
| 01:51 ET | 400 | 4.3 |
| 01:55 ET | 200 | 4.3 |
| 01:57 ET | 300 | 4.3 |
| 02:00 ET | 500 | 4.295 |
| 02:04 ET | 100 | 4.295 |
| 02:06 ET | 100 | 4.295 |
| 02:08 ET | 300 | 4.295 |
| 02:09 ET | 1600 | 4.29 |
| 02:11 ET | 200 | 4.295 |
| 02:13 ET | 730 | 4.295 |
| 02:15 ET | 200 | 4.295 |
| 02:18 ET | 800 | 4.29 |
| 02:20 ET | 300 | 4.295 |
| 02:22 ET | 200 | 4.295 |
| 02:24 ET | 500 | 4.29 |
| 02:26 ET | 2900 | 4.29 |
| 02:27 ET | 100 | 4.295 |
| 02:29 ET | 700 | 4.295 |
| 02:31 ET | 14391 | 4.2725 |
| 02:33 ET | 1898 | 4.275 |
| 02:38 ET | 1400 | 4.27 |
| 02:40 ET | 3600 | 4.285 |
| 02:42 ET | 6756 | 4.295 |
| 02:44 ET | 500 | 4.3 |
| 02:45 ET | 400 | 4.295 |
| 02:47 ET | 400 | 4.295 |
| 02:49 ET | 3097 | 4.285 |
| 02:51 ET | 400 | 4.28 |
| 02:54 ET | 300 | 4.28 |
| 02:56 ET | 3348 | 4.28 |
| 02:58 ET | 1200 | 4.29 |
| 03:00 ET | 200 | 4.285 |
| 03:02 ET | 800 | 4.28 |
| 03:03 ET | 600 | 4.285 |
| 03:05 ET | 3100 | 4.26 |
| 03:07 ET | 100 | 4.26 |
| 03:09 ET | 1100 | 4.265 |
| 03:12 ET | 200 | 4.27 |
| 03:14 ET | 1569 | 4.26 |
| 03:16 ET | 200 | 4.265 |
| 03:18 ET | 500 | 4.265 |
| 03:20 ET | 300 | 4.26 |
| 03:21 ET | 200 | 4.265 |
| 03:23 ET | 300 | 4.26 |
| 03:25 ET | 1121 | 4.2601 |
| 03:27 ET | 2504 | 4.25 |
| 03:30 ET | 500 | 4.25 |
| 03:32 ET | 1834 | 4.25 |
| 03:34 ET | 800 | 4.255 |
| 03:36 ET | 200 | 4.25 |
| 03:38 ET | 900 | 4.255 |
| 03:39 ET | 1200 | 4.255 |
| 03:41 ET | 4289 | 4.265 |
| 03:43 ET | 1400 | 4.26 |
| 03:45 ET | 1755 | 4.26 |
| 03:48 ET | 3931 | 4.245 |
| 03:50 ET | 5332 | 4.255 |
| 03:52 ET | 4848 | 4.255 |
| 03:54 ET | 4126 | 4.245 |
| 03:56 ET | 7447 | 4.24 |
| 03:57 ET | 5554 | 4.24 |
| 03:59 ET | 27467 | 4.24 |
Apr 1, 2024
DJ Acelyrin Price Target Maintained With a $28.00/Share by HC Wainwright & Co., from 6:57AM ET on Monday Apr 01, 2024 by Dow Jones
6:57AM ET on Monday Apr 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ACELYRIN Inc | 419.4M | -0.4x | --- |
Annexon Inc | 423.1M | -2.6x | --- |
Lexeo Therapeutics Inc | 411.8M | -4.6x | --- |
Larimar Therapeutics Inc | 410.9M | -7.7x | --- |
Tourmaline Bio Inc | 402.1M | -1.5x | --- |
LENZ Therapeutics Inc | 401.4M | -1.0x | --- |
Company Information
ACELYRIN, INC. is a late-stage clinical biopharma company. The Company is focused on providing treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The Company has two programs in late-stage clinical development. The Company’s lead product candidate, izokibep, is being evaluated in multiple immunologic indications, including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and uveitis. The Company is also developing Lonigutamab for the treatment of thyroid eye disease (TED), as well as developing SLRN-517 in chronic urticaria. Izokibep is an inhibitor of anti-interleukin (IL)-17A in phase III development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R being investigated for the treatment of TED. SLRN-517, a fully IgG1 human monoclonal antibody designed to target a distinct epitope of c-KIT.
Contact Information
- Headquarters
- 4149 Liberty Canyon RoadAGOURA HILLS, CA, United States 91301
- Phone
- 805-730-0360
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Bruce Cozadd
- Chief Executive Officer, Founder, Director
- Shao-lee Lin
- Interim Chief Financial Officer
- Gilbert Labrucherie
- Chief Operating Officer
- Melanie Gloria
- Chief Legal and Administrative Officer
- Mina Kim
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $419.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 98.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-10.84 |
Book Value | $6.71 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
